Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2564050 | 0.94 | HRH3 (0.55) | HRH3HRH1KDM4EMAPTTAAR1 | |
| SCHEMBL5223664 | 0.92 | HRH3 (0.55) | HRH3HRH1KDM4EMAPTTAAR1 | |
| SCHEMBL2564836 | 0.92 | HRH3 (0.55) | HRH3HRH1KDM4EMAPTTAAR1 | |
| SCHEMBL2566752 | 0.86 | HRH3 (0.49) | HRH3HRH1 | |
| SCHEMBL2563832 | 0.85 | HRH3 (0.50) | HRH3HRH1 | |
| SCHEMBL2563611 | 0.84 | HRH3 (0.70) | HRH3HRH1 | |
| SCHEMBL2563410 | 0.84 | HRH3 (0.70) | HRH3HRH1 | |
| SCHEMBL2560963 | 0.84 | HRH3 (0.70) | HRH3HRH1 | |
| Hydrochloric Acid SCHEMBL3552392 | 0.83 | HRH3 (0.69) | HRH3HRH1 | |
| SCHEMBL2563972 | 0.83 | HRH3 (0.55) | HRH3HRH1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960387-B1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | SANOFI SA (FR) | 2011-11-02 | — | — | EP | claimed |
| US-7678807-B2 | Isoquinoline and benzo[H] isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of the histamine H3 receptor | SANOFI-AVENTIS (FR) | 2010-03-16 | — | — | US | claimed |
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | claimed |
| EP-1960387-A1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | sanofi-aventis (FR) | 2008-08-27 | — | — | EP | claimed |
| WO-2007060027-A1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | SANOFI AVENTIS (FR) | 2007-05-31 | — | — | WO | claimed |
| EP-1960387-B1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | SANOFI SA (FR) | 2011-11-02 | — | — | EP | disclosed |
| US-7678807-B2 | Isoquinoline and benzo[H] isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of the histamine H3 receptor | SANOFI-AVENTIS (FR) | 2010-03-16 | — | — | US | disclosed |
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| EP-1960387-A1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | sanofi-aventis (FR) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060027-A1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | SANOFI AVENTIS (FR) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH1, HRH2 | HRH3 1/4885HRH1 2/4885DRD2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.